Galderma's Nemluvio Shows Deep, Lasting Skin Responses in Atopic Dermatitis Up to Three Years

The Quick Take

• Post-hoc data from Nemluvio's ARCADIA long-term extension study showed majority of Week 16 responders maintained responses for up to three years
• New data presented at Fall Clinical 2026 demonstrated consistent safety profile and sustained skin clearance, itch, and sleep improvements
• Nemluvio (nemolizumab) is approved for atopic dermatitis in patients aged 12 and older

Galderma's three-year long-term extension data for Nemluvio (nemolizumab) in atopic dermatitis represents a meaningful clinical differentiation from shorter-term competitors. The ARCADIA study post-hoc analysis confirms that patients who responded by Week 16 maintained deep and lasting skin clearance and itch control through three years of treatment — a durability profile that is increasingly critical for biologic prescribing decisions in chronic inflammatory conditions. This data readout at Fall Clinical 2026 positions Nemluvio ahead of potential label expansion and market share consolidation in a competitive IL-31 targeted therapy space.

For the atopic dermatitis market, three-year durability data carries commercial weight beyond clinical merit — payers and pharmacy benefit managers use long-term efficacy maintenance data as justification for biologic formulary positioning and reimbursement approvals. Galderma competes against established biologics including Dupixent (dupilumab) from Sanofi/Regeneron, which set the market benchmark, and Adbry (tralokinumab) from LEO Pharma. The age extension to include patients 12 and older broadens the addressable patient population and expands Galderma's commercial opportunity in pediatric and adolescent dermatology.

Watch for expanded Nemluvio label applications in additional age groups and potential new indications beyond atopic dermatitis — prurigo nodularis is a condition where nemolizumab has shown early promise. Galderma's upcoming full ARCADIA publication in a peer-reviewed journal will be the next catalyst for physician adoption. The macro variable is reimbursement policy trajectory in major markets: US Medicare negotiation scope, European health technology assessments, and private payer formulary inclusion all determine whether the clinical durability advantage translates into commercial market share.

Synthesized from 1 source.